A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Thomas Jefferson University
Genentech, Inc.
Eisai Inc.
Dana-Farber Cancer Institute
Genentech, Inc.
Dana-Farber Cancer Institute
Pfizer
Incyte Corporation
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
Olema Pharmaceuticals, Inc.
Amgen
Massachusetts General Hospital
UNC Lineberger Comprehensive Cancer Center
Pfizer
Ono Pharmaceutical Co. Ltd
University of Iowa
Thomas Jefferson University
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University of California, San Diego
Tvardi Therapeutics, Incorporated
Mirati Therapeutics Inc.
Georgetown University
Stanford University
West China Hospital
Jiangsu Simcere Pharmaceutical Co., Ltd.
Vanderbilt-Ingram Cancer Center
Hoffmann-La Roche
Peter MacCallum Cancer Centre, Australia
Royal Marsden NHS Foundation Trust
AstraZeneca
Dana-Farber Cancer Institute
Lebanese University
OHSU Knight Cancer Institute
Emory University
Lebanese University
Memorial Sloan Kettering Cancer Center
G1 Therapeutics, Inc.
Jonsson Comprehensive Cancer Center
Celcuity Inc
Hoffman Oncology
University of Texas Southwestern Medical Center
Emory University
University of California, San Francisco
Haihe Biopharma Co., Ltd.
Pediatric Brain Tumor Consortium
St. Jude Children's Research Hospital
Abramson Cancer Center at Penn Medicine
Georgetown University